This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Dec 10;40(35):4033-4036.

doi: 10.1200/JCO.22.01386. Epub 2022 Sep 2.

A New Dancing Partner for Venetoclax: Gilteritinib

Affiliations

PMID: 36054870
DOI: 10.1200/JCO.22.01386

Editorial

A New Dancing Partner for Venetoclax: Gilteritinib

Amir T Fathi. J Clin Oncol. 2022.

. 2022 Dec 10;40(35):4033-4036.

doi: 10.1200/JCO.22.01386. Epub 2022 Sep 2.

Author

Affiliation

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

PMID: 36054870
DOI: 10.1200/JCO.22.01386

No abstract available

PubMed Disclaimer

Comment on

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.